Novo Nordisk Invests DKK 8.5bn in Danish Rare Disease Production Facility
Novo Nordisk’s DKK 8.5bn investment in Odense facility supports rare disease treatments and sustainability.
Read exclusive Lab Industry press releases
Read opinion pieces and interviews from people across the industry
Read exclusive Lab Industry press releases
Read opinion pieces and interviews from people across the industry
Novo Nordisk’s DKK 8.5bn investment in Odense facility supports rare disease treatments and sustainability.